Literature DB >> 7093841

Clostridium difficile: epidemiology and clinical features.

T J Marrie, M Furlong, R S Faulkner, J Sidorov, E V Haldane, E A Kerr.   

Abstract

To determine the epidemiologic features of Clostridium difficile in Halifax, Nova Scotia, the authors studied two groups of hospitalized patients, one group of outpatients and a fourth group of 54 healthy subjects. The first group consisted of 29 patients with diarrhea, whose stool was found to contain C. difficile or its cytotoxin, or both. Twenty-two underwent sigmoidoscopic examinations; of these, 18 had abnormal colonic mucosa and 6 of the 18 had pseudomembranous colitis. In the second group of 127 patients on general medical wards, 22 (17%) carried C. difficile. Thirteen of the 22 had diarrhea, and 3 had pseudomembranous colitis. Clustering of patients with C. difficile was evident. In vitro production of toxin by isolates of C. difficile from these patients was more likely if antibiotics had been given. Only 1 (4.5%) of the 22 outpatients with various gastrointestinal disorders (group 3) and none of the 54 healthy subjects (group 4) carried C. difficile. The clinical spectrum of infection with C. difficile extended from asymptomatic patients to those with nonspecific colitis and pseudomembranous colitis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093841

Source DB:  PubMed          Journal:  Can J Surg        ISSN: 0008-428X            Impact factor:   2.089


  3 in total

1.  Restriction endonuclease analysis of nosocomial isolates of Clostridium difficile.

Authors:  H R Devlin; W Au; L Foux; W C Bradbury
Journal:  J Clin Microbiol       Date:  1987-11       Impact factor: 5.948

2.  Clostridium difficile colitis secondary to intravenous vancomycin.

Authors:  J R Hecht; E J Olinger
Journal:  Dig Dis Sci       Date:  1989-01       Impact factor: 3.199

Review 3.  Clostridium difficile: clinical disease and diagnosis.

Authors:  F C Knoop; M Owens; I C Crocker
Journal:  Clin Microbiol Rev       Date:  1993-07       Impact factor: 26.132

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.